Navamedic ASA (OSL:NAVA)
Norway · Delayed Price · Currency is NOK 18.80
-0.25 (-1.31%)
May 13, 2026, 4:25 PM CET
Navamedic ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 571.24 | 565.36 | 531.44 | 512 | 382.14 | 278.44 | |
Revenue Growth (YoY) | 5.28% | 6.38% | 3.80% | 33.98% | 37.24% | 32.67% |
Cost of Revenue | 353.02 | 347.79 | 325.92 | 313.63 | 218.62 | 166.7 |
Gross Profit | 218.22 | 217.57 | 205.52 | 198.37 | 163.52 | 111.74 |
Selling, General & Admin | 117.96 | 116.09 | 118.14 | 63.67 | 48.09 | 44.46 |
Amortization of Goodwill & Intangibles | 27.19 | 27.19 | 10.49 | 8.61 | 4.85 | 4.55 |
Other Operating Expenses | 52.98 | 53.86 | 40.82 | 83.13 | 63.75 | 49.12 |
Operating Expenses | 209.31 | 201.31 | 173.72 | 158.73 | 119.08 | 100.29 |
Operating Income | 8.91 | 16.25 | 31.8 | 39.64 | 44.45 | 11.46 |
Interest Expense | -17 | -14.56 | -10.01 | -7.77 | -0.61 | -2.5 |
Interest & Investment Income | 1.1 | 1.1 | 3.1 | 4.63 | 3.08 | 2.79 |
Earnings From Equity Investments | - | - | - | - | -1.1 | -3.19 |
Currency Exchange Gain (Loss) | -1.03 | 0.12 | -6.28 | 5.94 | -9.24 | -5.52 |
Other Non Operating Income (Expenses) | -1.99 | -1.99 | 6.91 | -6.43 | 13.58 | -0.68 |
EBT Excluding Unusual Items | -10.02 | 0.92 | 25.52 | 36.01 | 50.15 | 2.36 |
Merger & Restructuring Charges | -3.85 | -3.85 | - | -16.06 | - | - |
Gain (Loss) on Sale of Investments | 3.93 | -11.45 | -1.55 | -8.7 | -7.64 | - |
Other Unusual Items | -1.28 | -1.28 | -25.59 | -17.4 | - | - |
Pretax Income | -11.21 | -15.66 | -1.62 | -6.16 | 42.51 | 2.36 |
Income Tax Expense | 4.99 | 7.88 | 3.87 | 7.53 | 13.07 | 1.74 |
Earnings From Continuing Operations | -16.2 | -23.54 | -5.49 | -13.69 | 29.43 | 0.62 |
Net Income | -16.2 | -23.54 | -5.49 | -13.69 | 29.43 | 0.62 |
Net Income to Common | -16.2 | -23.54 | -5.49 | -13.69 | 29.43 | 0.62 |
Net Income Growth | - | - | - | - | 4662.46% | - |
Shares Outstanding (Basic) | 20 | 19 | 17 | 17 | 17 | 16 |
Shares Outstanding (Diluted) | 20 | 19 | 17 | 17 | 17 | 16 |
Shares Change (YoY) | 15.96% | 8.91% | 1.24% | 1.48% | 3.60% | 13.61% |
EPS (Basic) | -0.79 | -1.24 | -0.31 | -0.79 | 1.75 | 0.04 |
EPS (Diluted) | -0.79 | -1.24 | -0.31 | -0.79 | 1.73 | 0.04 |
EPS Growth | - | - | - | - | 4459.36% | - |
Free Cash Flow | 11.85 | 23.2 | 36.03 | -0.02 | 15.69 | -2.02 |
Free Cash Flow Per Share | 0.58 | 1.22 | 2.06 | -0.00 | 0.92 | -0.12 |
Gross Margin | 38.20% | 38.48% | 38.67% | 38.74% | 42.79% | 40.13% |
Operating Margin | 1.56% | 2.88% | 5.98% | 7.74% | 11.63% | 4.11% |
Profit Margin | -2.84% | -4.16% | -1.03% | -2.67% | 7.70% | 0.22% |
Free Cash Flow Margin | 2.07% | 4.10% | 6.78% | -0.00% | 4.11% | -0.73% |
EBITDA | 44.25 | 44.58 | 43.46 | 49.16 | 49.62 | 16.15 |
EBITDA Margin | 7.75% | 7.89% | 8.18% | 9.60% | 12.99% | 5.80% |
D&A For EBITDA | 35.34 | 28.33 | 11.66 | 9.52 | 5.18 | 4.69 |
EBIT | 8.91 | 16.25 | 31.8 | 39.64 | 44.45 | 11.46 |
EBIT Margin | 1.56% | 2.88% | 5.98% | 7.74% | 11.63% | 4.11% |
Effective Tax Rate | - | - | - | - | 30.76% | 73.79% |
Revenue as Reported | 571.24 | 565.36 | 531.44 | 512 | 382.14 | 278.44 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.